Services
Company
Legal and Governance
Publication Library / Publications
Cost-effectiveness of alternative strategies for vaccination of adolescents against serogroup B IMD with the MenB-FHbp vaccine in Canada
Objectives
Serogroup B meningococci (MnB) are now the largest cause of invasive meningococcal disease (IMD) in Canada. We assessed the clinical and economic impact of 3 adolescent MenB-FHbp immunization strategies.
Methods
A population-based dynamic transmission model was developed to simulate the transmission of MnB among the entire Canadian population over a 30-year time horizon. Age group-based IMD incidence, bacterial carriage and transmission, disease outcomes, costs, and impact on quality of life were obtained from Canadian surveillance data and published literature. The vaccine was assumed to provide 85% protection against IMD and 26.6% against carriage acquisition. The model estimated the impact of routine vaccination with MenB-FHbp in 3 strategies: (1) age 14, along with existing school-based programs, with 75% uptake; (2) age 17 with 75%uptake, assuming school vaccination; and (3) age 17 with 30%uptake, assuming vaccination outside of school. Costs were calculated from the Canadian societal perspective.
Results
With no vaccination, an estimated 3974 MnB cases would be expected over 30 years. Vaccination with strategies 1–3 were estimated to avert 688, 1033, and 575 cases, respectively. These outcomes were associated with incremental costs per quality-adjusted life-year of $976,000, $685,000, and $490,000.
Conclusion
Our model indicated that if the vaccine reduces risk of carriage acquisition, vaccination of older adolescents, even at lower uptake, could have a significant public health impact. Due to low disease incidence, MnB vaccination is unlikely to meet widely accepted cost-effectiveness thresholds, but evaluations of new programs should consider the overall benefits of the vaccination.
Authors
M C Breton, L Huang, S J Snedecor, N Cornelio, F Fanton-Aita
Journal
Canadian Journal of Public Health
Therapeutic Area
Other
Center of Excellence
Health Economic Modeling & Meta-analysis
Year
2020
Read full article